In neoadjuvant cetuximab-treated patients with HNSCC, upregulation of CD137 by intratumoral, cetuximab-activated NK cells correlated with FcγRIIIa V/F polymorphism and predicted clinical response. This evidence concerns the gene FCGR3A and head and neck squamous cell carcinoma.